Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.
This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was associated with induction of plasma tumor necrosis factor, interleukin (IL) 10 , IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-term follow-up. The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of therapy were positively correlated with the level of HBsAg decline at week 48. Thus, stopping or interrupting NA treatment should be further investigated as a strategy to accelerate HBsAg loss.
Department of Gastroenterology, Hepatology and Endocrinology.
Christoph
C
Höner Zu Siederdissen
Department of Gastroenterology, Hepatology and Endocrinology.|German Center for Infection Research, partner site Hannover-Braunschweig.
Franziska
F
Rinker
Department of Gastroenterology, Hepatology and Endocrinology.
Benjamin
B
Maasoumy
Department of Gastroenterology, Hepatology and Endocrinology.
Steffen B
SB
Wiegand
Institute of Biostatistics and Mathematical Modeling, Faculty of Medicine, Goethe-University, Frankfurt am Main, Germany.
Natalie
N
Filmann
Institute of Transplant Immunology, IFB-Tx, Hannover Medical School.
Christine S
CS
Falk
Department of Gastroenterology, Hepatology and Endocrinology.
Katja
K
Deterding
Department of Gastroenterology, Hepatology and Endocrinology.
Kerstin
K
Port
Department of Gastroenterology, Hepatology and Endocrinology.
Carola
C
Mix
Department of Gastroenterology, Hepatology and Endocrinology.|Institute of Transplant Immunology, IFB-Tx, Hannover Medical School.|German Center for Infection Research, partner site Hannover-Braunschweig.
Michael P
MP
Manns
Institute of Biostatistics and Mathematical Modeling, Faculty of Medicine, Goethe-University, Frankfurt am Main, Germany.
Eva
E
Herrmann
Department of Gastroenterology, Hepatology and Endocrinology.|Institute of Transplant Immunology, IFB-Tx, Hannover Medical School.|German Center for Infection Research, partner site Hannover-Braunschweig.
Heiner
H
Wedemeyer
Department of Gastroenterology, Hepatology and Endocrinology.|German Center for Infection Research, partner site Hannover-Braunschweig.
Anke R M
AR
Kraft
Department of Gastroenterology, Hepatology and Endocrinology.|German Center for Infection Research, partner site Hannover-Braunschweig.
Markus
M
Cornberg
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage*; D016207:Cytokines / Q000097:blood; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006512:Hepatitis B Core Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009705:Nucleosides / Q000008:administration & dosage*; D009711:Nucleotides / Q000008:administration & dosage*; D011446:Prospective Studies; D012008:Recurrence; D028761:Withholding Treatment
D000998:Antiviral Agents; D016207:Cytokines; D004279:DNA, Viral; D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens; D009705:Nucleosides; D009711:Nucleotides
CXCL10; HBsAg; IP-10; cytokines; hepatitis B virus infection; nucleos(t)ide analogues; stopping treatment